Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Almirall’s Full-Year 2022 Results: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall’s Full-Year 2022 Results


Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2022 financial results today.


Financial highlights (€ rounded million)

 

Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference


Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San

Almirall’s Nine-month 2022 Results: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall’s Nine-month 2022 Results


Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2022 financial results.



Financial highlights (€ rounded million)


 


9M 2022

Edison Investment Research Limited: Oryzon Genomics (ORY): Planning iadademstat's path to market
Edison Investment Research Limited: Oryzon Genomics (ORY): Planning iadademstat's path to market
Edison Investment Research Limited: Oryzon Genomics (ORY): Planning iadademstat's path to market